A carregar...
Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada
INTRODUCTION: Antimuscarinics are the principal pharmacological treatment for overactive bladder (OAB), but frequently give rise to anticholinergic side effects, such as dry mouth, a factor leading to poor persistence. The β(3)-adrenoceptor agonist mirabegron is devoid of significant anticholinergic...
Na minha lista:
| Publicado no: | Can Urol Assoc J |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Canadian Medical Association
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4662398/ https://ncbi.nlm.nih.gov/pubmed/26644809 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.3098 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|